Development and validation of a nomogram for predicting survival in patients with non-metastatic primary adenocarcinoma of the bladder.

Yu, Dong-Dong; Dong, Hui; Chen, Wei-Kang; Chen, Kun; Wu, Zhi-Gang; Li, Cheng-Di; Cai, Jian; Xiao, Yun-Bei

Yu, Dong-Dong; Dong, Hui; Chen, Wei-Kang; Chen, Kun; Wu, Zhi-Gang; Li, Cheng-Di; Cai, Jian; Xiao, Yun-Bei.

Afiliação

Yu DD; Department of Andrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Dong H; Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Chen WK; Department of Andrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Chen K; Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Wu ZG; Department of Andrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Li CD; Department of Andrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Cai J; Department of Andrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xiao YB; Department of Andrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Transl Cancer Res ; 9(9): 5155-5165, 2020 Sep.

Article em En | MEDLINE | ID: mdl-35117882

Palavras-chave

Cancer-specific survival (CSS); Surveillance, Epidemiology, and End Results (SEER); nomogram; non-metastatic primary adenocarcinoma of the bladder (NMACB)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google